These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19485758)

  • 1. Current status of toxoplasmosis vaccine development.
    Kur J; Holec-Gasior L; Hiszczyńska-Sawicka E
    Expert Rev Vaccines; 2009 Jun; 8(6):791-808. PubMed ID: 19485758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.
    Innes EA; Vermeulen AN
    Parasitology; 2006; 133 Suppl():S145-68. PubMed ID: 17274844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against Toxoplasma gondii: new developments and perspectives.
    Zhang NZ; Chen J; Wang M; Petersen E; Zhu XQ
    Expert Rev Vaccines; 2013 Nov; 12(11):1287-99. PubMed ID: 24093877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxoplasma gondii: protective effect of an intranasal SAG1 and MIC4 DNA vaccine in mice.
    Wang H; He S; Yao Y; Cong H; Zhao H; Li T; Zhu XQ
    Exp Parasitol; 2009 Jul; 122(3):226-32. PubMed ID: 19366622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toxoplasma gondii: perspectives for a vaccine].
    Gottstein B
    Schweiz Med Wochenschr Suppl; 1995; 65():89S-95S. PubMed ID: 7716458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice.
    Qu D; Wang S; Cai W; Du A
    Vaccine; 2008 Aug; 26(35):4541-8. PubMed ID: 18590785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination concepts against Toxoplasma gondii.
    Garcia JL
    Expert Rev Vaccines; 2009 Feb; 8(2):215-25. PubMed ID: 19196201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [DNA vaccines and recombinant antigens in prevention of Toxoplasma gondii infections--current status of the studies].
    Hiszczyńska-Sawicka E; Holec-Gasior L; Kur J
    Wiad Parazytol; 2009; 55(2):125-39. PubMed ID: 19670528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein-protein vaccine combination but not by its DNA-protein counterpart.
    Jongert E; Verhelst D; Abady M; Petersen E; Gargano N
    Vaccine; 2008 Sep; 26(41):5289-95. PubMed ID: 18675872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research?
    Innes EA
    Expert Rev Vaccines; 2010 Oct; 9(10):1117-9. PubMed ID: 20923261
    [No Abstract]   [Full Text] [Related]  

  • 11. Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice.
    Ismael AB; Dimier-Poisson I; Lebrun M; Dubremetz JF; Bout D; Mevelec MN
    J Infect Dis; 2006 Oct; 194(8):1176-83. PubMed ID: 16991094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a vaccine for toxoplasmosis: current status.
    Bhopale GM
    Microbes Infect; 2003 Apr; 5(5):457-62. PubMed ID: 12738002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice.
    Peng GH; Yuan ZG; Zhou DH; He XH; Liu MM; Yan C; Yin CC; He Y; Lin RQ; Zhu XQ
    Vaccine; 2009 Nov; 27(47):6570-4. PubMed ID: 19720368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis.
    Dziadek B; Gatkowska J; Brzostek A; Dziadek J; Dzitko K; Dlugonska H
    Exp Parasitol; 2009 Sep; 123(1):81-9. PubMed ID: 19508869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice.
    Cui YL; He SY; Xue MF; Zhang J; Wang HX; Yao Y
    Parasite Immunol; 2008 May; 30(5):309-13. PubMed ID: 18331395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The history of Toxoplasma gondii--the first 100 years.
    Dubey JP
    J Eukaryot Microbiol; 2008; 55(6):467-75. PubMed ID: 19120791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenetics of Toxoplasma gondii informs vaccine design.
    Henriquez FL; Woods S; Cong H; McLeod R; Roberts CW
    Trends Parasitol; 2010 Nov; 26(11):550-5. PubMed ID: 20580611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.
    Assolini JP; Concato VM; Gonçalves MD; Carloto ACM; Conchon-Costa I; Pavanelli WR; Melanda FN; Costa IN
    Parasitol Res; 2017 Jun; 116(6):1603-1615. PubMed ID: 28477099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic pulsed dendritic cells induce a protective immune response against Toxoplasma gondii.
    Bertaux L; Mevelec MN; Dion S; Suraud V; Gregoire M; Berthon P; Dimier-Poisson I
    Parasite Immunol; 2008; 30(11-12):620-9. PubMed ID: 19067843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii.
    Cong H; Gu QM; Yin HE; Wang JW; Zhao QL; Zhou HY; Li Y; Zhang JQ
    Vaccine; 2008 Jul; 26(31):3913-21. PubMed ID: 18555564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.